Form 4: Cartesian Therapeutics Chief Technology Officer Exercises and Sells Shares

Metin Kurtoglu, Chief Technology Officer of Cartesian Therapeutics, executed multiple transactions involving the exercise of stock options and the sale of common stock.

Summary

• Metin Kurtoglu, the Chief Technology Officer of Cartesian Therapeutics, engaged in a series of transactions involving the company's stock.
• On November 14, 2024, Mr. Kurtoglu exercised options to acquire 25,900 shares at $1.41 per share and sold 25,900 shares at weighted average prices ranging from $16.00 to $17.12.
• On November 15, 2024, he exercised options for 22,068 shares at $1.41 per share and sold 22,068 shares at weighted average prices ranging from $17.00 to $17.42.
• On November 18, 2024, Mr. Kurtoglu exercised options for 34,400 shares at $1.41 per share and sold 34,400 shares at weighted average prices ranging from $17.50 to $18.69.
• These transactions resulted in a net change in his holdings of common stock, with a final holding of 51,033 shares after the sales on November 18, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral report of insider transactions. It doesn't indicate positive or negative sentiment, but rather a factual record of stock option exercises and sales.

Risks

• The sale of a significant number of shares by a company officer could be perceived negatively by the market.
• The weighted average sale prices indicate a range of prices, which could introduce some volatility.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reported transactions are typical for executives who receive stock options as part of their compensation.
• The weighted average sale prices are within a reasonable range for the stock's trading activity.

Stakeholder Impact

• The transactions may have a minor impact on the stock price, depending on market perception of insider sales.
• Shareholders are informed of the transactions by a key executive.

Key Dates

Keywords

stock options, insider trading, common stock, share sales, Cartesian Therapeutics, Metin Kurtoglu